Literature DB >> 3714355

Altered antibody isotype in cystic fibrosis: possible role in opsonic deficiency.

R B Moss, Y P Hsu, M M Sullivan, N J Lewiston.   

Abstract

Patients with cystic fibrosis (CF) whose respiratory tracts are colonized with Pseudomonas aeruginosa (PA) may develop a specific opsonic deficiency for alveolar macrophage phagocytosis of PA. We examined the possible role of altered antibody (Ab) isotype in this phenomenon by measuring serum levels and distribution of IgG and IgG subclass Ab (IgG1, IgG2, IgG3, and IgG4) to the major opsonic immunodeterminant, serotype-specific lipopolysaccharide (LPS), by means of enzyme-linked immunosorbent assays employing monoclonal secondary antibodies, and comparing these results to the serum opsonic capacity in an in vitro murine alveolar macrophage phagocytic assay. Twenty-one patients with CF who were colonized with PA had approximately a 30-fold elevation of PA LPS IgG Ab levels and higher IgG subclass 1-4 Ab compared to 10 uncolonized patients with CF and 11 healthy controls (p less than 0.05-0.0005 depending on the isotype). Colonized patients with CF had a shift in PA LPS Ab distribution toward IgG3 compared to uncolonized patients with CF (p less than 0.02). A surprising finding was that uncolonized patients with CF had lower levels (p less than 0.05) and proportion (p less than 0.002) of PA LPS IgG2 Ab than controls, with an apparent shift to higher levels and proportion of PA LPS IgG4 (p less than 0.01). Serum from colonized patients with CF showed diminished opsonic capacity for phagocytosis of PA compared to uncolonized patients and controls (p less than 0.005), with 42% showing inhibitory activity. Functional Ab was also found to be inhibitory at high (greater than 500 ng/ml) concentrations. Serum opsonic capacity appeared to include a noncomplement cofactor for optimal activity.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3714355     DOI: 10.1203/00006450-198605000-00015

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  11 in total

Review 1.  Inflammation in the lung in cystic fibrosis. A vicious cycle that does more harm than good?

Authors:  M Berger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

2.  T-cell modulation of the antibody response to bacterial polysaccharide antigens.

Authors:  C E Taylor; R Bright
Journal:  Infect Immun       Date:  1989-01       Impact factor: 3.441

3.  Corticosteroid treatment in cystic fibrosis.

Authors:  J F Price; P Greally
Journal:  Arch Dis Child       Date:  1993-06       Impact factor: 3.791

Review 4.  Cystic fibrosis. 1. Pseudomonas aeruginosa infection in cystic fibrosis and its management.

Authors:  N Høiby; C Koch
Journal:  Thorax       Date:  1990-11       Impact factor: 9.139

5.  Antilipopolysaccharide antibodies and differential diagnosis of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.

Authors:  A Fomsgaard; B Dinesen; G H Shand; T Pressler; N Høiby
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948

6.  Neutrophil elastase cleaves C3bi on opsonized pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch.

Authors:  M F Tosi; H Zakem; M Berger
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

7.  Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.

Authors:  I Eichler; L Joris; Y P Hsu; J Van Wye; R Bram; R Moss
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

Review 8.  Cystic fibrosis. Infection and immunity to Pseudomonas.

Authors:  R U Sorensen; R L Waller; J D Klinger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

Review 9.  The relationship between atopy and cystic fibrosis.

Authors:  R W Wilmott
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

10.  Staphylococcus aureus capsular types and antibody response to lung infection in patients with cystic fibrosis.

Authors:  A Albus; J M Fournier; C Wolz; A Boutonnier; M Ranke; N Høiby; H Hochkeppel; G Döring
Journal:  J Clin Microbiol       Date:  1988-12       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.